<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089383</url>
  </required_header>
  <id_info>
    <org_study_id>ARETAIEION UNIVERSITY HOSPITAL</org_study_id>
    <nct_id>NCT05089383</nct_id>
  </id_info>
  <brief_title>Vaginal Versus Combined Use of Progesterone in Fresh IVF/ICSI Cycles</brief_title>
  <official_title>Vaginal Versus Combined Use of Progesterone in Fresh IVF/ICSI Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iaso Maternity Hospital, Athens, Greece</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: the combined use of progesterone administration for luteal phase support is&#xD;
      superior to the single route of progesterone administration in terms of pregnancy outcome&#xD;
      parameters in women undergoing fresh IVF/ICSI cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In ART (IVF/ICSI), most of the studies have shown a deficiency of progesterone during the&#xD;
      luteal phase, especially due to the use of GnRH analogs. The lack of progesterone leads to&#xD;
      abnormal endometrial development and consequently to desynchronization between the latter and&#xD;
      the blastocyst implantation. Therefore, it is a standard of care to use progesterone for&#xD;
      luteal phase support after embryo transfer and during the first trimester, in case of&#xD;
      pregnancy.&#xD;
&#xD;
      According to ESHRE guidelines, either of vaginal, oral, subcutaneous or intramuscular route&#xD;
      is advisable.&#xD;
&#xD;
      But, until now, there is no robust evidence on the effect on pregnancy outcome of the&#xD;
      combined route of progesterone administration compared to the standard of care (single&#xD;
      route).&#xD;
&#xD;
      The aim of this study is to compare the effectiveness of the combined route of progesterone&#xD;
      administration to the single route.&#xD;
&#xD;
      The study is a prospective cohort study. Participants will receive either standard treatment&#xD;
      with single route (vaginal) progesterone administration according to the ESHRE guidelines, or&#xD;
      combination of more than one routes of administration, that is vaginal plus oral or&#xD;
      subcutaneous progesterone, starting afterthe fresh embryo transfer until 12 weeks of&#xD;
      gestation or a negative pregnancy test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>9 months]</time_frame>
    <description>The percentage of viable embryo after 20 weeks of gestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>20 weeks</time_frame>
    <description>Loss of pregnancy up to 20 weeks of gestation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">698</enrollment>
  <condition>Luteal Phase</condition>
  <arm_group>
    <arm_group_label>combined progesterone group</arm_group_label>
    <description>patients will receive vaginal plus subcutaneous or per os progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal progesterone group</arm_group_label>
    <description>patients will receive vaginal progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Utrogestan</intervention_name>
    <description>PROSPECTIVE STUDY</description>
    <arm_group_label>Vaginal progesterone group</arm_group_label>
    <arm_group_label>combined progesterone group</arm_group_label>
    <other_name>PROLUTEX,VASCLOR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile couples with an indication for IVF/ICSI (both Units).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a documented history of infertility, aged 22-40, undergoing fresh embryo&#xD;
             transfer after IVF/ICSI, under informed consent.&#xD;
&#xD;
          -  Physiological menstrual cycles (24-35 days), normal endocrine function (FSH ≤ 15 IU /&#xD;
             ml), transvaginal ultrasound without pathological findings, free personal medical&#xD;
             history, indication for IVF/ICSI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endocrine or metabolic disorders, e.g., PCO (S), pathology of the uterus and/or&#xD;
             endometrium, basal FSH levels&gt; 15 IU / ml, major surgery in the ovaries (removal), and&#xD;
             age &lt;22 years and &gt; 40 years old.&#xD;
&#xD;
          -  Active pelvic inflammatory disease&#xD;
&#xD;
          -  IVF/ICSI with donor eggs&#xD;
&#xD;
          -  Previous participation in this trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaos Vlachos</last_name>
    <role>Study Director</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vasiliki Dourou</last_name>
    <phone>+306977706799</phone>
    <email>vdourou@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikolaos Vlachos</last_name>
    <email>nfvlahos@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National and Kapodistrian University of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Vlahos, Prof</last_name>
      <email>nfvlahos@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Vassiliki Dourou, Midwife</last_name>
      <phone>6977706799</phone>
      <phone_ext>0030</phone_ext>
      <email>vdourou@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015 Jul 7;(7):CD009154. doi: 10.1002/14651858.CD009154.pub3. Review.</citation>
    <PMID>26148507</PMID>
  </reference>
  <reference>
    <citation>Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008 Apr;89(4):789-92. doi: 10.1016/j.fertnstert.2008.02.012.</citation>
    <PMID>18406835</PMID>
  </reference>
  <reference>
    <citation>Pabuçcu E, Pabuçcu R, Gürgan T, Tavmergen E. Luteal phase support in fresh and frozen embryo transfer cycles. J Gynecol Obstet Hum Reprod. 2020 Jun 22:101838. doi: 10.1016/j.jogoh.2020.101838. [Epub ahead of print] Review.</citation>
    <PMID>32585391</PMID>
  </reference>
  <reference>
    <citation>Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017 May 1;32(5):1019-1027. doi: 10.1093/humrep/dex023. Erratum in: Hum Reprod. 2017 Oct 1;32(10):2152.</citation>
    <PMID>28333318</PMID>
  </reference>
  <reference>
    <citation>Baker VL, Jones CA, Doody K, Foulk R, Yee B, Adamson GD, Cometti B, DeVane G, Hubert G, Trevisan S, Hoehler F, Jones C, Soules M. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Hum Reprod. 2014 Oct 10;29(10):2212-20. doi: 10.1093/humrep/deu194. Epub 2014 Aug 6.</citation>
    <PMID>25100106</PMID>
  </reference>
  <reference>
    <citation>Tomic V, Kasum M, Vucic K. The role of luteal support during IVF: a qualitative systematic review. Gynecol Endocrinol. 2019 Oct;35(10):829-834. doi: 10.1080/09513590.2019.1603288. Epub 2019 Apr 29.</citation>
    <PMID>31032676</PMID>
  </reference>
  <reference>
    <citation>Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018 Dec 1;33(12):2212-2221. doi: 10.1093/humrep/dey306.</citation>
    <PMID>30304457</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Nikos Vlahos</investigator_full_name>
    <investigator_title>Professor of Obstetrics, Gynecology and Assisted Reproduction</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>PROGESTERONE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

